human microbiome News
-
MedBiome licenses the RapidAIM technology from the University of Ottawa
MedBiome is pleased to announce that it has exclusively licensed the RapidAIM technology from the University of Ottawa. RapidAIM is a revolutionary assay to rapidly determine the effects of compounds on individual human living microbiomes. RapidAIM fidelity maintains functional living human microbiomes in 96 well plates and allows the testing of drugs for their effects on the ...
-
MedBiome licenses the MetaLab metaproteomic software
MedBiome is pleased to announce that it has licensed the iMetaLab software platform from the University of Ottawa. iMetaLab (imetalab.ca) is a leading bioinformatics software for metaproteomics data analysis. MedBiome uses the iMetaLab software in combination with the RapidAIM assay to identify Precision Microbiome Therapeutics that change the composition of the human microbiome, ...
-
Microbiologists’ work adds to research on microbiome fungi and childhood disease
A surge in research projects on the human microbiome - the complex ecosystem of microorganisms in the human gastrointestinal tract - is bolstering scientific understanding of health, disease and environment. Much of the research has focused on gut bacteria and viruses, leaving a third factor - fungi - little studied. An international consortium of scientists has conducted the first large-scale ...
-
Evofuel to participate in the 2019 International Castor Oil Association - ICOA Conference
Evofuel Ltd., a company focused on securing the global demand for stable castor oil supply and a wholly owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today that its CEO, Mr. Assaf Dotan, will present at 2019 ICOA Conference to take place on the 21st-23rd of May, 2019 in Dubrovnick, Croatia. Mr. Assaf Dotan will present the company’s new vision and branding. The ...
By Evogene Ltd.
-
SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)
PRLog - SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC). "By granting an Orphan Drug Designation to SFA001, FDA has given a special status to treatment of the most prevalent form of liver cancer. This ODD designation will provide SFA ...
-
Rebiotix, Inc. and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research
Rebiotix Inc, a Ferring Pharmaceuticals company, announced today that their Chief Scientific Officer, Dr. Ken Blount, has been appointed to Karolinska Institutet’s Joint Steering Committee (JSC) of the Centre for Translation Microbiome Research (CTMR) in Stockholm, Sweden. Dr. Blount joins two colleagues from Ferring Pharmaceuticals currently serving on the JSC – Per Falk, M.D., ...
-
Intus Bio’s management system certified to ISO 9001
Intus Bio, a microbiome research company that develops tools for characterizing microbiome populations down to the strain level, has been awarded ISO 9001:2015 certification. The company received the certificate for its management system on Nov. 4, 2020. It recognizes Intus Bio’s commitment to quality through an effective quality management system. ISO 9001:2015 is a standard issued by ...
-
Evogene Financial Results for the First Quarter of 2019 Earnings Announcement Schedule
Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it will release its financial results for the first quarter of 2019 on Tuesday, May 28, 2019. Dr. Arnon Heyman, CEO of Evogene’s cannabis subsidiary, Canonic, will join the conference call to discuss the company’s activity with highlights from ...
By Evogene Ltd.
-
Symberix Awarded Multiple SBIR Grants from National Institutes of Health to Develop Proprietary Microbiome-Targeted Drugs
Symberix, a leader in the discovery of drugs that selectively target the human microbiome, announced today that it has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH). These grants will fund the research of new drugs that safely and selectively inhibit a bacterial enzyme responsible for a number of dose-limiting gastrointestinal (GI) ...
-
JSR, the collaborative research facility "JSR BiRD" in Kawasaki, invites KINS Co., Ltd.
JSR Corporation (Head Office: Minato-ku, Tokyo, Representative Director and CEO: Eric Johnson, JSR Corporation) announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome, for the Collaborative Lab, a collaborative research facility for startups, which was established in a new research laboratory at the "JSR Bioscience ...
-
Microviable Therapeutics to enter into a contractual agreement with BCD Bioscience
Microviable Therapeutics SL (Gijón, Asturias, Spain), announced a contractual agreement with BCD Bioscience Inc. (California, USA) to work on microbial fermentation and novel prebiotics to modulate the human gut microbiome. Microviable expertise on gut microbiome research will enable to conveniently process microbiota samples for fermentation applications that coupled with BCD ...
-
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
The collaboration aims to create standardised, stabilised live microbiota-based formulations addressing bacterial vaginosis (BV), a common vaginal infection among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues1,2,3 The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this ...
-
Microvi and Nexilico Develop Powerful Computational Platform for Gut Microbiome funded by NIH
Under a National Institute of Health (NIH) grant awarded by the National Institute of General Medical Sciences (NIGMS), Microvi, Nexilico, and their research partners have developed a first-of-its-kind predictive computational platform focused on the gut microbiome and its interaction with therapeutics. The in silico platform reduces the cost and timeframe of drug development by reducing the ...
-
MetaboGen and BioGaia initiates program for microbiome restoration
Today, MetaboGen and BioGaia have agreed to initiate a new development program addressing restoration of the microbiome after antibiotic treatment. The program will combine expertise and experience from both companies and is part of the long-term relationship between MetaboGen and BioGaia. For background, read more here: The microbiome has gained considerable interest as modulators of health ...
By Metabogen AB
-
Symberix Announces Non-Dilutive Funding Support for Lead Programs
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded three Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH), entered into a Research Collaboration Agreement with the NIH’s National Center for Advancing Translational Sciences (NCATS), and ...
-
Intus Bio’s Partners with Inqaba Biotechnical Industries to Accelerate Microbiome Research in Sub-Saharan Africa
Intus Bio, a microbiome research company that develops complete solutions for characterizing microbiome populations down to the strain level, has entered into a partnership with Inqaba Biotechnical Industries (Pty) Ltd for product distribution and StrainID™ services in Sub-Saharan Africa. Inqaba Biotechnical Industries (Pty) Ltd, trading as inqaba biotec™, is a unique South African ...
-
Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
Enrollment completion for the first Phase 3 clinical trial in microbiome industry Largest randomized, double-blinded study, with over 300 patients enrolled aimed to demonstrate the potential benefit of RBX2660 in reducing rates of recurrent Clostridioides difficile (C. diff) infection Rebiotix intends to use the results from the Phase 3 trial to serve as the basis for licensure application to ...
-
Intus Bio Announces New Canadian Distribution Partnership with D-Mark Biosciences to Accelerate Microbiome Research
Intus Biosciences, a microbiome research company that develops complete solutions for characterizing microbiome populations down to the strain level, has entered into a distribution partnership for the promotion, sale and support of all Intus Biosciences products and software in Canada. “Canada is experiencing significant growth in microbiome research,” said Duane Mendis, General ...
-
City of Hope and Osel Announce Exclusive License for Intellectual Property on the use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic Applications
City of Hope®, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, and Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use ...
By Osel Inc.
-
Intus Bio Announces New Distribution Partnership with BioCat GmbH to Accelerate Microbiome Research in Germany, Austria and Switzerland
Intus Bios, a microbiome research company that develops complete solutions for characterizing microbiome populations down to the strain level, has entered into an exclusive distribution partnership with BioCat GmbH, a leading provider of life sciences solutions, for the promotion, sale and support of all Intus Biosciences products and software in Germany, Austria, and Switzerland. Founded in ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you